Full-Time
Finance Manager
Robotics & Automation, Apex
Novanta
1,001-5,000 employees
Provides core photonics for medical tech
No salary listed
Apex, NC, USA
In Person
 Finance & Banking (1) |
|---|
- Possess academic qualifications in Accounting, Finance, or related fields.
- Possess extensive experience in financial management, supporting problem-solving and decision-making.
- Be able to analyze complex financial data and communicate findings effectively.
- Knowledge of accounting principles and financial systems.
- Be detail-oriented and possess excellent organizational skills, with an ability to prioritize and multi-task.
- The Finance Manager oversees budgeting, forecasting, and analysis, ensuring accurate financial reporting.
- They advise senior management to drive growth and profitability.
- Managing and analyzing financial statements and reports.
- Preparing and presenting financial forecasts and budget plans.
- Collaborating with other departments to ensure financial alignment and management.
- Managing cash flow and investment strategies.
- Identifying areas for cost reduction and profit maximization Timeliness of creating forecasts, budgets, reports & analysis; consistently meets deadlines.
- Consistently high level of accuracy & reasonableness, of financial forecasts, reports & analysis.
- None
Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Bedford, Texas
Founded
1968
Simplify's Take
What believers are saying
- Medical Solutions revenue grew 15% in Q1 2026; bookings surged 37% with 1.10 book-to-bill ratio.
- AI data center applications growing 20% year-over-year, expanding addressable market beyond traditional surgical robotics.
- Novanta deploys $1.5B acquisition capacity targeting medical technologies and bioprocessing through 2026.
What critics are saying
- Intuitive Surgical's da Vinci 6 integrates in-house precision components, displacing Novanta's motion subsystems.
- Tariffs and freight costs compress gross margins 100 basis points; manufacturing transfers delay M&A deployment.
- Customer concentration in GPU drilling exposes 15% revenue cliff if Nvidia diversifies suppliers post-2026.
What makes Novanta unique
- Precision motion control and force sensing enable next-generation surgical robotics with millimeter-level accuracy.
- Novanta Growth System extracts synergies from acquisitions, sustaining 45%+ gross margins through disruptions.
- Sole-source supplier for AI data center GPU drilling, capturing 15% of Q1 2026 revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Performance Bonus
Company News
As Q4 earnings season concludes, the nine electronic components stocks tracked showed strong performance, with revenues beating analyst consensus estimates by 3%. Share prices rose 5.2% on average since results were announced. Novanta posted revenues of $258.3 million, up 8.5% year-on-year, but fell short of analyst expectations by 0.9%. The company delivered the weakest performance against estimates in the group, with significant EBITDA misses. Its stock has dropped 17.4% since reporting, currently trading at $117.59. Allient led the group, reporting revenues of $143.4 million, up 17.5% year-on-year and beating expectations by 7.5%. The company also exceeded EBITDA estimates. Its shares have risen 6.3% since reporting, trading at $66.01.
Health Lean Analytics, a Barcelona-based startup automating hospital data collection, has raised over €2.1 million in a financing round combining private capital and public funding. US-listed Novanta joined as a technology and strategic partner, securing board representation. The round included an oversubscribed €1.4 million seed funding from family offices Inderhabs, Namarel and Braincats, plus a participative loan from Spain's National Innovation Company. Founded in 2023, HLA develops AI-powered hospital operations platforms that passively capture real-time clinical and operational data, particularly in surgical suites. The startup's technology integrates with existing hospital systems, using large language models to transform data into actionable insights. The funding will support domestic consolidation and US market entry within 12 months, whilst strengthening R&D capabilities in data automation and AI.
Harvey Partners disclosed a new position in Novanta, acquiring 304,000 shares worth $36.17 million during the quarter ending 17 February 2026, according to an SEC filing. The stake now represents 3.21% of the fund's reportable assets under management. Novanta, which provides photonics, vision and precision motion components for medical and industrial applications, has seen its shares remain roughly flat over the past year at around $145, significantly underperforming the S&P 500's 16% gain. The company reported revenue of $980.6 million in 2025, up 3% year over year, but operating income fell to $94 million from $110.6 million, whilst net income dropped from $64.1 million to $53.8 million. CEO Matthijs Glastra said the company plans to improve margins and cash flow this year.
Novanta CEO Matthijs Glastra sold 7,500 common shares worth approximately $1.09 million on 10 February 2026, according to an SEC Form 4 filing. Following the transaction, Glastra holds 57,367 shares directly and 54,382 shares indirectly through a trust, with direct holdings valued at $8.3 million. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in September 2025, indicating routine liquidity management rather than concerns about company performance. The transaction matches Glastra's largest trade size in his 10 sell-only transactions since February 2023. Novanta manufactures photonics, vision and precision motion components for medical and industrial sectors, reporting $960.31 million in trailing twelve-month revenue and employing 3,000 people.
Novanta Inc. reported record fourth-quarter revenue and a return to organic growth, driven by a 25% surge in bookings across all business units. The precision technology company benefited from AI-driven demand in robotics, serving as the sole-source supplier for precision drilling of high-density GPU boards. Medical technology now represents 53% of total sales, with double-digit growth in consumables. However, the company experienced margin pressure due to regional manufacturing transfers, creating a temporary 100 basis point headwind. For 2026, Novanta projects mid-single-digit organic growth and 100 basis points of gross margin expansion once manufacturing transfers complete by Q2. The company plans to deploy nearly $1.5 billion in acquisition capacity towards medical technologies and bioprocessing. Operating cash flow is forecast at $145 million to $185 million.